You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

141 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pirtobrutinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
binimetinib (Unfunded),
encorafenib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
riTUXimab,
vinCRIStine,
DOXOrubicin,
cyclophosphamide,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
tarlatamab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    letrozole
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
letrozole
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    anastrozole
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
anastrozole
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    exemestane
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
exemestane
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abemaciclib,
tamoxifen
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2025
Guidelines and Advice
Status: Current
Updated
Mar 2025
Guidelines and Advice
Updated
Mar 2025
Guidelines and Advice
Status: Current
Updated
Mar 2025
Drug
Other Name(s): Verzenio®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025

Pages